AR and pachyonychia congenita: Initially, to identify a suitable cell line model for the AR-targeting drug enzalutamide, we performed dose–response experiments in a panel of five PC cell lines with AR expression (LAPC-4, LNCaP, and C4) or without AR expression (PC3 and DU145), respectively13.